公开(公告)号：US20040001852A1

公开(公告)日：2004-01-01

申请号：US10465645

申请日：2003-06-20

Applicant: NEOVACS 11, RUE PERNETY

Inventor： Daniel A. Zagury ,  Jean-Francois Zagury

IPC: A61K039/21 ,  C07K014/16

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/084 ,  C07K16/1036 ,  C07K16/1072 ,  C07K2319/21 ,  C07K2319/55 ,  C12N2710/20022 ,  C12N2740/14022 ,  C12N2740/16322

Abstract: The invention concerns the use of a protein derived from cancer cells, virus-infected cells or immune-defence cells or a fragment of said protein, characterized in that said protein is initially an immunosuppressive and/or angiogenic protein with local activity and said properties are inactivated by at least 70%, through a physical and/or chemical treatment, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed afainst said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, to obtain a medicine for use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer agent. The invention also concerns the resulting immunogenic compounds, their preparation method and their uses.

Abstract translation: 本发明涉及使用衍生自癌细胞，病毒感染细胞或免疫防御细胞或所述蛋白质片段的蛋白质，其特征在于所述蛋白质最初是具有局部活性的免疫抑制和/或血管生成蛋白质，并且所述性质是 通过物理和/或化学处理，通过遗传重组或辅助调理灭活至少70％，所述处理保持其被定位在所述蛋白质上的抗体鉴定的性质，并保留足够的免疫原性以产生中和或阻断的抗体 所述天然蛋白质，以获得用作局部抗免疫抑制和/或抗血管生成剂作为抗癌剂的药物。 本发明还涉及所得的免疫原性化合物，其制备方法及其用途。